202103 Mar
Nordic Bioscience Welcomes Investment from KKR for Next Phase of Growth
General News

Nordic Bioscience has world-leading knowledge and ownership of biomarkers, measurable indicators of biological change or response used for the development of diagnostic tools and identification of new drug candidates. “ I am excited to welcome KKR as a valued investor to the Nordic Bioscience team and to have their support in building on our strategy of bringing innovative novel diagnostic biomarkers and drug candidates to the market for the benefit of patients. In addition, Nordic Bioscience services a growing international customer base of pharma, biotech and CROs with preclinical and clinical data analysis from its certified laboratory. “ On the basis of our exceptional knowledge of the ECM, we are a sought-after partner to the world’s leading global health care companies and now have a base to accelerate our international development,” said Morten Karsdal. Dr. Claus Christiansen, together with his wife Dr. Bente Juel Riis, has during the last three decades founded and been involved with several successful biotechnology companies, including among others Osteometer, CCBR Synarc, Sanos Clinic, and Radius Health in addition to Nordic Bioscience.

  • Web and Content Management
  • Content Management